title: [The Oxygen effect: an old new target?].
abstract: The Oxygen effect plays a key role in cellular response to ionizing radiations. From many years, tumour hypoxia is a limiting treatment factor. Multiple ways to interact with free radicals have been developed. The increase in tissue oxygenation has a limited impact. Radiosensitizing agents as nimorazole or gadolinium have a clinical benefit. Tirapazamine or AQ4N, bioreductive agents, are not routinely used. New agents through the HIF-1 and the endothelial cell pathways are currently being developed. Studies on the expression of endogenous markers of hypoxia could be useful tools to predict tumour response to the treatment.
authors.affiliation: Département Universitaire de Radiothérapie, Centre Oscar-Lambret et Université Lille-II, 3, rue Frédéric-Combemale, Lille, France. e-lartigau@o-lambret.fr
authors.forename: E
authors.initials: E
authors.lastname: Lartigau
authors.forename: S
authors.initials: S
authors.lastname: Dewas
authors.forename: L
authors.initials: L
authors.lastname: Gras
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D015687:Cell Hypoxia; D006801:Humans; D006931:Hyperbaric Oxygenation; D009369:Neoplasms / Q000378:metabolism / Q000628:therapy*; D011355:Prodrugs / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant
chemical_list: D000970:Antineoplastic Agents; D011355:Prodrugs; D011838:Radiation-Sensitizing Agents